Physician profile
Audrey Coo
NPI 1114928124
$3,241.50
in general payments reported to CMS, 2019-2025
19 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $259 · 2021: $240 · 2022: $618 · 2023: $708 · 2024: $379 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Education: $21.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.28 |
| Education | $21.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $875.72 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $837.55 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $292.57 | 2021-2023 | Acthar |
| Novartis Pharmaceuticals Corporation | $244.37 | 2023-2025 | |
| Vifor Pharma, INC. | $179.83 | 2019-2022 | |
| Amgen INC. | $166.43 | 2019-2022 | |
| Travere Therapeutics, INC. | $151.49 | 2023-2025 | Filspari |
| Janssen Pharmaceuticals, INC | $118.81 | 2020 | |
| Mallinckrodt Enterprises LLC | $113.85 | 2019 | |
| Fresenius USA Marketing, INC. | $50.44 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.65 | 2022-2023 | |
| Ardelyx, INC. | $28.42 | 2024 | Ibsrela |
| Calliditas Therapeutics US INC. | $25.53 | 2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $24.20 | 2023 | Lupkynis |
| Akebia Therapeutics INC | $21.27 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuwellis, INC. | $20.48 | 2020 | |
| La Jolla Pharmaceutical Company | $20.16 | 2021 | |
| Glaxosmithkline, LLC. | $20.02 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Coo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.